<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03788382</url>
  </required_header>
  <id_info>
    <org_study_id>FOUNTAIN</org_study_id>
    <nct_id>NCT03788382</nct_id>
  </id_info>
  <brief_title>Failure to Adjuvant Therapy After Pancreatic Resection for Pancreatic Cancer</brief_title>
  <acronym>FOUNTAIN</acronym>
  <official_title>Failure to Adjuvant Therapy After Pancreatic Resection for Pancreatic Cancer: a Real Life Scenario</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita di Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universita di Verona</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the rate of patients submitted to pancreatic resection for&#xD;
      pancreatic cancer, who fail to access to adjuvant therapy or do not complete adjuvant&#xD;
      therapy. The purpose is to give an overview concerning the most frequent conditions and/or&#xD;
      reasons associated with failure or omission of adjuvant therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective observational study will evaluate all patients submitted to pancreatic&#xD;
      resection for pancreatic cancer.&#xD;
&#xD;
      The rate of omission to adjuvant therapy and rate of failure of completion of adjuvant&#xD;
      therapy will be evaluated as primary outcomes. As secondary outcomes, survival analyses will&#xD;
      be performed to investigate whether these factors influence prognosis, that will be evaluated&#xD;
      through a disease free survival analysis at 18-months. Epidemiological and perioperative data&#xD;
      will be analyzed to identify conditions associated with the primary outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients who fail to receive adjuvant therapy and reasons for that</measure>
    <time_frame>6 months</time_frame>
    <description>The amount of patients who will not receive adjuvant therapy after pancreatic resection for malignancy (when do indication exists) will be recorded</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of patients who fail to complete adjuvant therapy and reasons for that</measure>
    <time_frame>9 months</time_frame>
    <description>The amount of patients who will not complete adjuvant therapy after pancreatic resection for malignancy will be recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival of patients enrolled</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Pancreatic Malignant Neoplasm Primary</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients submitted to Pancreatic Resection for Pancreatic Cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of pancreatic cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non exocrine pancreatic tumors&#xD;
&#xD;
          -  Periampullary malignancies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Verona Hospital</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Paiella, MD</last_name>
      <phone>00393283342248</phone>
      <email>salvatore.paiella@univr.it</email>
    </contact>
    <investigator>
      <last_name>Salvatore Paiella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicola Quintarelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Bassi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Salvia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Cattelani, Med Stud</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 21, 2018</study_first_submitted>
  <study_first_submitted_qc>December 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2018</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universita di Verona</investigator_affiliation>
    <investigator_full_name>Salvatore Paiella, MD</investigator_full_name>
    <investigator_title>Salvatore Paiella, MD, Universit√† di Verona</investigator_title>
  </responsible_party>
  <keyword>Failure Adjuvant Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

